Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain

NCT02778399 is registered in ClinicalTrials.gov with ObsEva SA as lead sponsor.

NCT NCT02778399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02778399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Lead sponsor
ObsEva SA
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
July 1, 2019
Enrollment
328 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis